CYP17 Gene and Breast Cancer Risk
Author Information
Author(s): Gudmundsdottir K, Thorlacius S, Jonasson J G, Sigfusson B F, Tryggvadottir L, Eyfjord J E
Primary Institution: Icelandic Cancer Society
Hypothesis
Is there an association between the CYP17 polymorphism and breast cancer risk in relation to BRCA2 status?
Conclusion
The study found no major role for the CYP17 promoter polymorphism in breast cancer risk among males or females.
Supporting Evidence
- Breast cancer is the most common cancer among women in Iceland.
- Only one mutation has been found in each of the BRCA genes in Iceland.
- The CYP17 gene is involved in steroid hormone production, which may influence breast cancer risk.
Takeaway
This study looked at a gene that might affect breast cancer risk, but it didn't find strong evidence that it does.
Methodology
The study included male and female breast cancer cases and controls, genotyping the CYP17 polymorphism and analyzing BRCA2 status.
Limitations
The sample size for male breast cancer cases was small, which may limit the findings.
Participant Demographics
The study included 39 male breast cancer cases and 500 female breast cancer cases, with controls matched for age and health status.
Statistical Information
P-Value
P=0.32
Confidence Interval
95% CI, 1.04–4.27
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website